Cargando…
Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
BACKGROUND: To establish the combination of doxorubicin (DOX) and silybin (SLB) in oral hepatic-targeting liposomes with the goal of reducing cardiotoxic side effects and improve oral hepatoma treatment. METHODS: Distearoylphosphatidylethanolamine–polyethylene glycol–cholic acid-modified liposomes (...
Autores principales: | Li, Ying, Yang, Dandan, Wang, Yian, Li, Zhan, Zhu, Chunyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314320/ https://www.ncbi.nlm.nih.gov/pubmed/30643408 http://dx.doi.org/10.2147/IJN.S187888 |
Ejemplares similares
-
Supersaturated polymeric micelles for oral silybin delivery: the role of the Soluplus–PVPVA complex
por: Zhu, Chunliu, et al.
Publicado: (2019) -
Engineered Silybin Nanoparticles Educe Efficient Control in Experimental Diabetes
por: Das, Suvadra, et al.
Publicado: (2014) -
Nanoceria-mediated delivery of doxorubicin enhances the anti-tumour efficiency in ovarian cancer cells via apoptosis
por: Das, Joydeep, et al.
Publicado: (2017) -
Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2
por: Xu, Peng, et al.
Publicado: (2018) -
Anti-Cancer Efficacy of Silybin Derivatives - A Structure-Activity Relationship
por: Agarwal, Chapla, et al.
Publicado: (2013)